Most Recent Articles by Stan Grossman
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
Glucocerebrosidase gene mutation has been found to be strongly associated with REM sleep behavior disorder.
More Articles by Stan Grossman
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- In Stroke, No Clear Benefit for Head Positioning